Adrenal incidentalomas (AI) are very common and mostly they are non-functioning adenomas (NFA). NFAs are often associated with insulin resistance and metabolic syndrome. Several biomarkers, including certain growth factors, may participatein the pathogenesis ofmetabolic changes in patients with adrenal adenomas.Patients with NFA and age-matched control subjects were enrolled in the study. Data on age, gender, presence of metabolic syndrome or its components were obtained for each subject. Blood samples were obtained and glycemia, insulinemia, lipid profile, and selected growth factor levels were measured. Forty-three patients with NFA and 40 controls were included in the study. Differences were not found in the metabolic syndrome and its components prevalence or in the biochemical profile between patients and the control group. Significant differences were noticed in the levels of IGF1, IGF2, and IGFBP3 (p=0.016, p=0.005, p=0.004, respectively), but there were no differences in VEGF or EGF concentrations. In NFA patients, an association between glycemia and EGF levels was present (p=0.026). No significant correlations between tumor size and insulin or growth factor concentrations were present in AI patients. Significantly higher serum IGF1, IGF2, and IGFBP3 concentrations in NFA patients may support the role of the IGF axis in the pathogenesis of adrenocortical lesions.No correlation between IGFs or IGFBP3 and parameters of glucose or lipid metabolism was found. Present results may support the role of the growth hormone axis rather than hyperinsulinemia and insulin resistance in the pathogenesis of adrenocortical adenomas.

1st Department of Internal Medicine Faculty of Medicine P J Šafárik University Košice Slovakia

Zobrazit více v PubMed

ADACHI Y, NOJIMA M, MORI M, HIMORI R, KUBO T, YAMANO HO, LIN Y, WAKAI K, TAMAKOSHI A. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and the incidence of malignant neoplasms in a nested case-control study. Cancer Prev Res (Phila) 2020 doi: 10.1158/1940-6207.CAPR-19-0375. PubMed DOI

ADAM P, HAHNER S, HARTMANN M, HEINRICH B, QUINKLER M, WILLENBERG HS, SAEGER W, SBIERA S, SCHMULL S, VOELKER HU, STROBEL P, ALLOLIO B, FASSNACHT M. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathol. 2010;23:1596–1604. doi: 10.1038/modpathol.2010.153. PubMed DOI

AKKUS G, EVRAN M, SERT M, TETIKER T. Adipocytokines in non-functional adrenal incidentalomas and relation with insulin resistance parameters. Endocr Metab Immune Disord Drug Targets. 2019;19:326–332. doi: 10.2174/1871530318666181009112042. PubMed DOI

ALTIERI B, COLAO A, FAGGIANO A. The role of insulin-like growth factor system in the adrenocortical tumors. Minerva Endocrinol. 2019;44:43–57. doi: 10.23736/S0391-1977.18.02882-1. PubMed DOI

ALTIERI B, TIRABASSI G, DELLA CASA S, RONCHI CL, BALERCIA G, ORIO F, PONTECORVI A, COLAO A, MUSCOGIURI G. Adrenocortical tumors and insulin resistance: What is the first step? Int J Cancer. 2016;138:2785–2794. doi: 10.1002/ijc.29950. PubMed DOI

ANDERLOVÁ K, CINKAJZLOVÁ A, ŠIMJÁK P, KLOUČKOVÁ J, KRATOCHVÍLOVÁ H, LACINOVÁ Z, KAVÁLKOVÁ P, KREJČÍ H, MRÁZ M, PAŘÍZEK A, HALUZÍK M, KRŠEK M. Insulin-like growth factor axis in pregnancy and gestational diabetes mellitus. Physiol Res. 2019;68:807–816. doi: 10.33549/physiolres.934093. PubMed DOI

ANEKE-NASH CS, XUE X, QI Q, BIGGS ML, CAPPOLA A, KULLER L, POLLAK M, PSATY BM, SISCOVICK D, MUKAMAL K, STRICKLER HD, KAPLAN RC. The association between IGF-I and IGFBP-3 and incident diabetes in an older population of men and women in the cardiovascular health study. J Clin Endocrinol Metab. 2017;102:4541–4547. doi: 10.1210/jc.2017-01273. PubMed DOI PMC

ANGELOUSI A, KYRIAKOPOULOS G, NASIRI-ANSARI N, KARAGEORGOU M, KASSI E. The role of epithelial growth factors and insulin growth factors in the adrenal neoplasms. Ann Transl Med. 2018;6:253. doi: 10.21037/atm.2018.05.52. PubMed DOI PMC

BAHADIR CT, ECEMIS GC, ATMACA H. Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma? J Endocr Investig. 2018;41:1317–1323. doi: 10.1007/s40618-018-0869-1. PubMed DOI

BUCHANAN CM, PHILLIPS AR, COOPER GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J. 2001;360:431–439. doi: 10.1042/bj3600431. PubMed DOI PMC

DELIBASI T, KARBEK B, BOZKURT NC, CAKIR E, GUNGUNES A, UNSAL OO, ASLAN MS, CAKAL E. Circulating E-selectin levels and insulin resistance are associated with early stages of atherosclerosis in nonfunctional adrenal incidentaloma. Arch Endocrinol Metab. 2015;59:310–317. doi: 10.1590/2359-3997000000053. PubMed DOI

DESAI NA, PATEL SS. Increased insulin-like growth factor-1 in relation to cardiovascular function in polycystic ovary syndrome: friend or foe? Gynecol Endocrinol. 2015;31:801–807. doi: 10.3109/09513590.2015.1075497. PubMed DOI

Di DALMAZI G. Adrenal incidentaloma: picking out the high-risk patients. Exp Clin Endocrinol Diabetes. 2019;127:178–184. doi: 10.1055/a-0713-0598. PubMed DOI

Di DALMAZI G. Update on the risks of benign adrenocortical incidentalomas. Curr Opinion Endocrinol Diab Obes. 2017;24:193–199. doi: 10.1097/MED.0000000000000341. PubMed DOI

ELHASSAN YS, ALAHDAB F, PRETE A, DELIVANIS DA, KHANNA A, PROKOP L, MURAD MH, O’REILLY MW, ARLT W, BANCOS I. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Int Med. 2019;171:107–116. doi: 10.7326/M18-3630. PubMed DOI

ERMETICI F, MALAVAZOS AE, CORBETTA S, MORRICONE L, DALL’ASTA C, CORSI MM, AMBROSI B. Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism. 2007;56:686–692. doi: 10.1016/j.metabol.2006.12.018. PubMed DOI

FAICAL S, MACIEL RM, NOSE-ALBERTI V, SANTOS MC, KATER CE. Immunodetection of insulin-like growth factor I (IGF-I) in normal and pathological adrenocortical tissue. Endocr Pathol. 1998;9:63–70. doi: 10.1007/BF02739953. PubMed DOI

FASSNACHT M, ARLT W, BANCOS I, DRALLE H, NEWELL-PRICE J, SAHDEV A, TABARIN A, TERZOLO M, TSAGARAKIS S, DEKKERS OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175:G1–G34. doi: 10.1530/EJE-16-0467. PubMed DOI

FOLTYN W, STRZELCZYK J, MAREK B, KAJDANIUK D, SIEMIŃSKA L, ROSIEK V, KOS-KUDŁA B. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas. Endokrynol Pol. 2012;63:22–28. PubMed

GUILLAUD-BATAILLE M, RAGAZZON B, De REYNIES A, CHEVALIER C, FRANCILLARD I, BARREAU O, STEUNOU V, GUILLEMOT J, TISSIER F, RIZK-RABIN M, RENE-CORAIL F, AL GHUZLAN A, ASSIE G, BERTAGNA X, BAUDIN E, LE BOUC Y, BERTHERAT J, CLAUSER E. IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. PloS one. 2014;9:e103744. doi: 10.1371/journal.pone.0103744. PubMed DOI PMC

HARADA K, HANAYAMA Y, OBIKA M, ITOSHIMA K, OKADA K, OTSUKA F. Clinical relevance of insulin-like growth factor-1 to cardiovascular risk markers. Aging Male. 2019:1–9. doi: 10.1080/13685538.2019.1657083. PubMed DOI

ILVESMAKI V, LIU J, HEIKKILA P, KAHRI AI, VOUTILAINEN R. Expression of insulin-like growth factor binding protein 1–6 genes in adrenocortical tumors and pheochromocytomas. Horm Metab Res. 1998;30:619–623. doi: 10.1055/s-2007-978945. PubMed DOI

JAWIARCZYK-PRZYBYLOWSKA A, WOJTCZAK B, WHITWORTH J, SUTKOWSKI K, BIDLINGMAIER M, KORBONITS M, BOLANOWSKI M. Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules. Endokrynol Pol. 2019;70:213–217. doi: 10.5603/EP.a2019.0005. PubMed DOI

KADAKIA R, JOSEFSON J. The relationship of insulin-like growth factor 2 to fetal growth and adiposity. Horm Res Paediatr. 2016;85:75–82. doi: 10.1159/000443500. PubMed DOI

KASPRZAK A, KWASNIEWSKI W, ADAMEK A, GOZDZICKA-JOZEFIAK A. Insulin-like growth factor (IGF) axis in cancerogenesis. Mutat Res Rev Mutat Res. 2017;772:78–104. doi: 10.1016/j.mrrev.2016.08.007. PubMed DOI

KHAN U. Nonfunctioning and subclinical cortisol secreting adrenal incidentalomas and their association with metabolic syndrome: A systematic review. Indian J Endocrinol Metab. 2019;23:332–346. doi: 10.4103/ijem.IJEM_52_19. PubMed DOI PMC

KOOL MM, GALAC S, Van der HELM N, CORRADINI S, KOOISTRA HS, MOL JA. Insulin-like growth factor-phosphatidylinositol 3 kinase signaling in canine cortisol-secreting adrenocortical tumors. J Vet Intern Med. 2015;29:214–224. doi: 10.1111/jvim.12528. PubMed DOI PMC

LIVINGSTONE C, BORAI A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin Endocrinol. 2014;80:773–781. doi: 10.1111/cen.12446. PubMed DOI

MURPHY LJ. The role of the insulin-like growth factors and their binding proteins in glucose homeostasis. Exp Diabesity Res. 2003;4:213–224. doi: 10.1155/EDR.2003.213. PubMed DOI PMC

MUSCOGIURI G, De MARTINO MC, NEGRI M, PIVONELLO C, SIMEOLI C, ORIO F, PIVONELLO R, COLAO A. Adrenal mass: insight into pathogenesis and a common link with insulin resistance. Endocrinology. 2017;158:1527–1532. doi: 10.1210/en.2016-1804. PubMed DOI

OBRADOVIC M, ZAFIROVIC S, SOSKIC S, STANIMIROVIC J, TRPKOVIC A, JEVREMOVIC D, ISENOVIC ER. Effects of IGF-1 on the cardiovascular system. Curr Pharm Design. 2019;25:3715–3725. doi: 10.2174/1381612825666191106091507. PubMed DOI

PAPANASTASIOU L, ALEXANDRAKI KI, ANDROULAKIS II, FOUNTOULAKIS S, KOUNADI T, MARKOU A, TSIAVOS V, SAMARA C, PAPAIOANNOU TG, PIADITIS G, KALTSAS G. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up. Clin Endocrinol. 2017;86:488–498. doi: 10.1111/cen.13294. PubMed DOI

PATEL D, ELLIS R, HOWARD B, BOUFRAQECH M, GARA SK, ZHANG L, QUEZADO MM, NILUBOL N, KEBEBEW E. Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma. Annals Surg Oncol. 2014;21:3541–3547. doi: 10.1245/s10434-014-3768-5. PubMed DOI

POURIAMEHR S, BARMAKI H, RASTEGARY M, LOTFI F, NABI AFJADI M. Investigation of insulin-like growth factors/insulin-like growth factor binding proteins regulation in metabolic syndrome patients. BMC Res Notes. 2019;12:653. doi: 10.1186/s13104-019-4492-9. PubMed DOI PMC

QIN HY, SUN H, WANG X, BAI R, LI Y, ZHAO J. Correlation between CT perfusion parameters and microvessel density and vascular endothelial growth factor in adrenal tumors. PLoS One. 2013;8:e79911. doi: 10.1371/journal.pone.0079911. PubMed DOI PMC

SCHMITT A, SAREMASLANI P, SCHMID S, ROUSSON V, MONTANI M, SCHMID DM, HEITZ PU, KOMMINOTH P, PERREN A. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology. 2006;49:298–307. doi: 10.1111/j.1365-2559.2006.02505.x. PubMed DOI

SHANMUGALINGAM T, BOSCO C, RIDLEY AJ, Van HEMELRIJCK M. Is there a role for IGF-1 in the development of second primary cancers? Cancer Med. 2016;5:3353–3367. doi: 10.1002/cam4.871. PubMed DOI PMC

TERZOLO M, BOSSONI S, ALI A, DOGA M, REIMONDO G, MILANI G, PERETTI P, MANELLI F, ANGELI A, GIUSTINA A. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J Clin Endocrinol Metab. 2000;85:1310–1315. doi: 10.1210/jcem.85.3.6531. PubMed DOI

WLODARCZYK B, BORKOWSKA A, WLODARCZYK P, MALECKA-PANAS E, GASIOROWSKA A. Serum levels of insulin-like growth factor 1 and insulin-like growth factor-binding protein 2 as a novel biomarker in the detection of pancreatic adenocarcinoma. J Clin Gastroenterol. 2019 doi: 10.5114/pg.2020.95091. PubMed DOI

WLODARCZYK B, GASIOROWSKA A, MALECKA-PANAS E. The role of insulin-like growth factor (IGF) axis in early diagnosis of pancreatic adenocarcinoma (PDAC) J Clin Gastroenterol. 2018;52:569–572. doi: 10.1097/MCG.0000000000001073. PubMed DOI

XIE ZL, YE PS, ZHANG SK, ZHANG YS, SHEN XZ. Endogenous LPS alters liver GH/IGF system gene expression and plasma lipoprotein lipase in goats. Physiol Res. 2015;64:721–729. doi: 10.33549/physiolres.932854. PubMed DOI

YARDEN Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37:S3–S8. doi: 10.1016/S0959-8049(01)00230-1. PubMed DOI

ZHANG J, WANG C, GAO J, SUN J, ZENG X, WU S, LIANG Z. Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status. Diagn Pathol. 2014;9:19. doi: 10.1186/1746-1596-9-19. PubMed DOI PMC